J&J Split To Have Limited China Business Impact?
Lessons From Earlier Moves
Executive Summary
China is a major emerging market for J&J’s pharma, medical and consumer health businesses and the planned spinout of the consumer business is likely to allow the US giant to focus on key new drugs in a fast-changing and competitive market while retaining medtech growth. But the consumer sector will continue to face challenges and might learn from similar moves by other multinationals in China.
You may also be interested in...
J&J Continues Signaling Aggressive M&A Approach To Drive Growth
Johnson & Johnson reported disappointing Q1 sales for its COVID-19 vaccine but called the Carvykti launch solid and discussed plans for further diversification of its multiple myeloma portfolio.
J&J’s Consumer Health Spinout Plan Surprises, But Seen As Sensible
Analysts say the pharma’s plan would separate out a unit with less growth and lower margins – and some predict a further breakup of the pharma and medical device units.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.